These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3769384)

  • 1. Influence of food on the bioavailability of spironolactone.
    Overdiek HW; Merkus FW
    Clin Pharmacol Ther; 1986 Nov; 40(5):531-6. PubMed ID: 3769384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the pharmacokinetics of spironolactone.
    Overdiek HW; Hermens WA; Merkus FW
    Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
    Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
    J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolism and biopharmaceutics of spironolactone in man.
    Overdiek HW; Merkus FW
    Rev Drug Metab Drug Interact; 1987; 5(4):273-302. PubMed ID: 3333882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bioavailability studies of two spironolactone-preparations (author's transl)].
    Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
    Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.
    Sungaila I; Bartle WR; Walker SE; DeAngelis C; Uetrecht J; Pappas C; Vidins E
    Gastroenterology; 1992 May; 102(5):1680-5. PubMed ID: 1568578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
    Krause W; Karras J; Seifert W
    Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
    Kaukonen AM; Lennernäs H; Mannermaa JP
    J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
    Rosenthal J; Jaeger H; Specker M
    Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone. I. Disposition and metabolism.
    Karim A; Zagarella J; Hribar J; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
    Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
    Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Heazlewood V
    Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.